Temozolomide is an oral chemotherapy medicine taken by mouth. It works by interfering with the DNA of cancer cells, which can help stop the tumor from growing or spreading. In this study it is given as part of the treatment plan to see how well it works alone or together with other drugs.

Gemcitabine is a chemotherapy drug given through a vein (intravenous). It blocks the ability of cancer cells to make new DNA, which can cause the cells to die. The trial uses gemcitabine to test its effect on shrinking tumors when used by itself or in combination with other agents.

Paclitaxel is an IV chemotherapy medication that stops cancer cells from dividing by stabilizing their internal structure. It is administered through a vein and is being studied to see how it contributes to tumor reduction, either alone or with other treatments.

Paclitaxel Albumin‑Bound (often called nab‑paclitaxel) is a form of paclitaxel that is attached to albumin particles, allowing it to be given intravenously without some of the solvents used in regular paclitaxel. This can sometimes reduce side effects. In the trial it is tested for its ability to help shrink tumors.

Carboplatin is an IV chemotherapy drug that damages the DNA of cancer cells, leading to cell death. It is included in the study to evaluate its effectiveness in controlling tumor growth when used alone or with other drugs.

Navlimetostat is an oral, film‑coated tablet that belongs to a newer class of medicines targeting specific pathways in cancer cells. Patients take it by mouth, and the trial is looking at how well it can stop tumor growth, either by itself or together with other agents.

Pemetrexed is an intravenous chemotherapy medication that blocks the production of nucleotides, the building blocks of DNA and RNA, which cancer cells need to multiply. The study uses pemetrexed to see how it affects tumor size when used alone or in combination.

Cisplatin is a well‑known IV chemotherapy drug that forms cross‑links in DNA, preventing cancer cells from dividing and causing them to die. It is being tested in the trial to determine its impact on tumor shrinkage, either as a single agent or with other treatments.

Pumitamig (BNT327) is an experimental drug given as a concentrate for infusion into a vein. It is being studied at different strengths (20 mg/ml and 50 mg/ml) to evaluate its potential to reduce tumor size, either by itself or when combined with other therapies.

BMS‑986504 is the investigational medicine that is the main focus of this study. It is given by mouth (or possibly by infusion, depending on the study design) and works by targeting a specific pathway that may be important in tumors with a missing MTAP gene. The trial is testing how well BMS‑986504 can shrink tumors when used alone or together with the other drugs listed above.

Metastatic solid tumor with homozygous MTAP deletion – These are cancers that have spread from their original organ to other parts of the body. The tumors lack both copies of the MTAP gene, which can affect how the cancer cells grow and divide. As the condition progresses, existing tumors may become larger and new tumor sites can appear in distant tissues. The disease typically follows a pattern of gradual expansion and increasing tumor burden.